Group 1 - The board of directors of Yuyuan Pharmaceutical Group Co., Ltd. received a resignation letter from independent director Ms. Cheng Hua due to personal reasons [1] - Ms. Cheng will resign from her positions as the independent director, chairperson of the audit committee, and member of the nomination committee, and will no longer hold any position in the company after her resignation [1] - The resignation will take effect after the shareholders' meeting elects a new independent director, as it will result in the number of independent directors being less than one-third of the board members [1] Group 2 - The company expresses gratitude for Ms. Cheng's contributions during her tenure as an independent director, highlighting her diligence and positive impact on the company's operations [2] - The company is actively preparing for the election of a new independent director to ensure compliance with legal regulations regarding board composition [1][2]

证券日报网讯9月11日晚间，悦康药业发布公告称，公司董事会于近日收到独立董事程华女士递交的书 面辞职报告。程华女士因个人原因申请辞去公司第二届董事会独立董事职务，同时辞去公司第二届董事 会审计委员会主任委员、提名委员会委员职务。辞职后，程华女士将不再担任公司任何职务。 ...

证券代码：688658 证券简称：悦康药业 公告编号：2025-039 悦康药业集团股份有限公司 关于公司独立董事离任的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 悦康药业集团股份有限公司（以下简称"公司"）董事会于近日收到独立董事 程华女士递交的书面辞职报告。程华女士因个人原因申请辞去公司第二届董事会 独立董事职务，同时辞去公司第二届董事会审计委员会主任委员、提名委员会委 员职务。辞职后，程华女士将不再担任公司任何职务。截至本公告披露日，程华 女士未持有公司股份，不存在应当履行而未履行的承诺事项。现将具体情况公告 如下： 一、 董事离任的基本情况 的辞职将自公司股东会选举产生新任独立董事后生效。在此之前，程华女士仍将 按照有关法律法规和《公司章程》的规定继续履行相应职责。公司将按照有关规 定，尽快完成独立董事的补选工作，确保董事会的构成符合法律法规的规定。 程华女士在担任公司独立董事期间恪尽职守、勤勉尽责，对公司规范运作发 挥了积极作用。公司董事会对程华女士在担任前述职务期间为公司及董事会工作 所作 ...

Core Points - The company announced the resignation of independent director Cheng Hua due to personal reasons [1] - Cheng Hua also stepped down from her roles as chair of the audit committee and member of the nomination committee [1] - Her resignation will take effect after the election of a new independent director at the company's shareholders' meeting [1] - Cheng Hua will continue to fulfill her responsibilities until the new director is appointed [1] - The company aims to complete the election of a new independent director promptly to ensure compliance with legal regulations regarding the board composition [1]

Core Insights - The company, Yuyuan Pharmaceutical, held a performance briefing for the first half of 2025, highlighting its innovative drug projects that include small nucleic acids, mRNA vaccines, peptide drugs targeting viral membrane fusion inhibitors, small molecule drugs, and innovative traditional Chinese medicine [1] Drug Development Progress - The broad-spectrum coronavirus membrane fusion inhibitor peptide drug YKYY017 is currently in the II/III clinical stage [1] - The potential best-in-class ultra-long-acting siRNA lipid-lowering drug YKYY015 has completed the Ia clinical trial [1] - The ultra-long-acting antihypertensive drug YKYY029 targeting the AGT gene has received IND approval in both China and the United States, with domestic phase I clinical trials progressing steadily [1] - The company is also advancing a potential best-in-class functional cure for hepatitis B and other innovative drugs, including RSV membrane fusion inhibitor peptide YKYY018 and therapeutic mRNA lyophilized vaccine YKYY031 [1] Business Development and Regulatory Updates - The company has intensified its global business development efforts this year by participating in international conferences [1] - In response to investor inquiries about the progress of three new drug applications, the management provided updates on traditional Chinese medicine innovative drugs, which are currently in various stages of development [1] - The management addressed concerns regarding the slow progress of the CT102 clinical trial, stating that it has completed the IIa clinical trial and is currently analyzing data to formulate subsequent clinical trial plans and strategies [1]

Core Viewpoint - The article highlights the strong performance and growth potential of Yuekang Pharmaceutical, particularly in the innovative drug sector, driven by significant R&D investments and a robust pipeline of products [4][5][17]. Financial Performance - In the first half of the year, Yuekang Pharmaceutical reported a revenue of 1.167 billion, with R&D investment amounting to 209 million, representing 17.91% of revenue, a year-on-year increase of 7.54% [4][6]. Industry Context - The innovative drug sector is recognized as one of the "new five flowers" in the current A-share technology bull market, alongside semiconductors, internet software and hardware, new energy, and robotics [5]. R&D Capabilities - Yuekang Pharmaceutical has established eleven major technology platforms focusing on nucleic acid drugs, peptide drugs, high-end traditional Chinese medicine, high-end chemical drugs, and AI drug development, making it one of the few companies with capabilities in mRNA vaccines and small nucleic acid drugs [6][8]. Product Pipeline - As of June 30, 2025, Yuekang has 42 projects in development, with 21 innovative drugs, including 12 nucleic acid drugs, 3 peptide drugs, 5 traditional Chinese medicines, and 1 chemical drug, indicating a rich and tiered pipeline [6][17]. Upcoming Drug Approvals - Three innovative traditional Chinese medicine drugs are expected to be approved soon, which will fill clinical treatment gaps and enhance Yuekang's competitiveness in the traditional medicine sector [7]. High-Value Nucleic Acid Drugs - Yuekang's subsidiary, Tianlong Pharmaceutical, is a key player in nucleic acid drug development, with significant advancements in AI target discovery and delivery systems, positioning the company with a competitive edge in the market [8][9]. Innovative Peptide Drugs - The company is developing a broad-spectrum peptide drug for coronavirus infections, which is set to enter phase III clinical trials, showcasing its innovative approach to treatment [10]. mRNA Vaccine Development - Yuekang has developed a robust mRNA vaccine technology platform, including self-replicating mRNA vaccines and unique delivery systems, which enhance efficacy and stability [11]. AI Drug Development Platform - The company has created a comprehensive AI drug development platform that streamlines the drug discovery process, significantly reducing development time and costs [12][13]. Global Expansion and Licensing Potential - Yuekang's international strategy includes establishing a global R&D team and pursuing FDA approvals early in the drug development process, indicating strong potential for overseas licensing opportunities [14][16]. siRNA Drug Development - Yuekang has two siRNA drugs in the U.S. clinical approval process, with one expected to be the first of its kind in the market, highlighting the company's innovative capabilities in gene therapy [15][16].

Group 1 - The innovative drug concept stocks are experiencing significant activity, with Jimin Health hitting the daily limit up [1] - JianKai Technology has seen an increase of over 10% [1] - Other companies such as YueKang Pharmaceutical, NuoSiGe, QianYan Bio, XinLiTai, and Chengdu XianDao are also following the upward trend [1]

Group 1 - The core viewpoint of the article highlights a significant rise in innovative drug concept stocks, with notable increases in share prices for several companies [1] Group 2 - Yuyuan Pharmaceutical experienced a rise of over 10% in its stock price [1] - Frontier Biotech saw an increase of over 9% in its stock price [1] - Changshan Pharmaceutical, Boteng Co., and Fuyuan Pharmaceutical also reported substantial gains, leading the market [1]

Core Viewpoint - Yuyuan Pharmaceutical experienced a 5.16% increase in stock price, reaching 28.95 CNY per share, with a trading volume of 1.59 billion CNY and a market capitalization of 13.028 billion CNY [1] Company Overview - Yuyuan Pharmaceutical Group Co., Ltd. is located in Beijing Economic and Technological Development Zone and was established on August 14, 2001, with its listing date on December 24, 2020 [1] - The company focuses on the research and production of high-end chemical drugs, with major revenue contributions from cardiovascular drugs, digestive system drugs, diabetes medications, and anti-infection drugs [1] - Key products contributing significantly to revenue include Ginkgo biloba extract injection, Tianma injection, Lansoprazole injection, Omeprazole enteric-coated capsules, Metformin sustained-release tablets, Cefuroxime sodium injection, and Ceftriaxone sodium injection [1] - The revenue composition is as follows: cardiovascular drugs 55.67%, anti-infection 20.88%, raw materials 8.73%, digestive system 6.87%, diabetes 4.85%, others 2.62%, and technical services 0.02% [1] Shareholder Information - Southern Fund's Southern Medical Health Flexible Allocation Mixed A Fund (000452) is among the top ten circulating shareholders of Yuyuan Pharmaceutical, holding 7.2677 million shares, unchanged from the previous period, representing 1.62% of circulating shares [2] - The fund has achieved a year-to-date return of 51.91%, ranking 599 out of 8254 in its category, and a one-year return of 48.77%, ranking 2666 out of 8037 [2] Fund Management - The fund manager of Southern Medical Health Flexible Allocation Mixed A is Wang Zhengjiao, who has been in the position for 7 years and 39 days, managing a total fund size of 2.417 billion CNY [3] - During Wang's tenure, the best fund return was 70.35%, while the worst was -53.83% [3] Fund Holdings - Southern Medical Health Flexible Allocation Mixed A Fund holds 7.2677 million shares of Yuyuan Pharmaceutical, unchanged from the previous period, making it the third-largest holding in the fund, accounting for 5.72% of the fund's net value [4]

Investment Rating - The report provides a positive outlook on the MASH non-invasive diagnosis technology, suggesting it could accelerate new drug development in the pharmaceutical and biotechnology sector [2]. Core Insights - The pharmaceutical and biotechnology sector experienced a decline of 0.65% from August 25 to August 29, underperforming compared to the Wind All A index (1.9%) and the CSI 300 index (2.71%). Only the medical research outsourcing (4.9%) and other biological products (0.14%) sectors saw gains, while in vitro diagnostics (-4.12%), raw materials (-3.34%), and vaccines (-0.59%) faced significant declines [2][7]. - The FDA has accepted the proposal for using VCTE-LSM as a reasonable alternative endpoint for clinical trials in adults with MASH and moderate to advanced fibrosis. This non-invasive method is expected to enhance patient compliance and could lead to a surge in drug development in the MASH area within the next two to three years [2][13]. - The report emphasizes the potential for domestic companies in China to leverage their cost advantages and forward-looking strategies in the field of non-invasive companion diagnostics, particularly in the MASH drug development competition [2]. Market Weekly Review - The pharmaceutical and biotechnology sector's performance was notably weaker than the broader market indices, with specific sub-sectors like medical research outsourcing and other biological products showing resilience [7][8]. - Individual stocks such as Tianchen Medical (30.1%), Ailis (25.6%), and Maiwei Biotech-U (22.4%) performed well, while stocks like Lifang Pharmaceutical (-13.9%), Yuekang Pharmaceutical (-11.9%), and Kanghua Biotech (-11.1%) faced significant losses [10][12]. Industry News and Key Company Announcements - On August 28, Kangfang Biotech announced that its drug AK112 received approval for treating advanced non-squamous non-small cell lung cancer, with promising clinical trial results expected to be presented at an international conference [12]. - The report highlights various companies' financial performances, with notable revenue changes and profit margins, indicating a mixed outlook across the sector [16][17].